Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Short-term Investments (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Short-term Investments for 7 consecutive years, with $491.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Short-term Investments rose 33.32% to $491.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $491.3 million, a 33.32% increase, with the full-year FY2025 number at $491.3 million, up 33.32% from a year prior.
  • Short-term Investments was $491.3 million for Q4 2025 at Kymera Therapeutics, up from $392.7 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $491.3 million in Q4 2025 to a low of $264.9 million in Q4 2023.
  • A 5-year average of $359.0 million and a median of $357.6 million in 2023 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: soared 58.7% in 2024, then decreased 25.48% in 2025.
  • Kymera Therapeutics' Short-term Investments stood at $394.4 million in 2021, then dropped by 14.11% to $338.8 million in 2022, then decreased by 21.8% to $264.9 million in 2023, then surged by 39.1% to $368.5 million in 2024, then soared by 33.32% to $491.3 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Short-term Investments are $491.3 million (Q4 2025), $392.7 million (Q3 2025), and $329.6 million (Q2 2025).